Utilization of a Visualization Software Tool for Deep Brain Stimulation Programming in a Subset of Subjects with Parkinson’s Disease Who Participated in the INTREPID Randomized Clinical Trial
Objective: This report will describe the utilization and parameters associated with the use of a new visualization tool for Deep Brain Stimulation (DBS) programming in…Application of Deep Neuronal Networks for the extraction of spectral characteristics in patients with Parkinson’s disease
Objective: We analyze and compare the spectral bands of electroencephalograms (EEGs) associated to motor activation for both patients with Parkinson's disease (PD) and healthy patients…Sexual Dysfunction Among Patients with Parkinson’s Disease in Dakar Senegal
Objective: The aim of this study was to describe the sexual disorder in patients that have Parkinson’s disease at Fann University Hospital in Dakar, Senegal.…Parkinson’s Disease patients with diplopia exhibit visuospatial and visuoperceptive impairment
Objective: In this study, we investigated Parkinson’s disease (PD) patients with and without diplopia using motor and non-motor assessments, including detailed neuropsychological testing. We hypothesized…Is Chronotype a biomarker for depression in military Veterans with Parkinson’s disease?
Objective: To determine the association of different chronotypes with depression in military Veterans with Parkinson's disease (PD). Background: Depression is a common non-motor symptom in…Evaluation of Birth Order in Parkinson’s Disease
Objective: This study compares PD patients with healthy control subjects in terms of being given birth as the first child. Background: It is known that…Frequency of Impulse Control Disorders and Other Related Behaviors in People with Parkinson’s Disease
Objective: To identify the frequency of impulse control disorders (ICDs) and other related behaviors (i.e. punding, hobbyism, walkabout and dopamine dysregulation syndrome) in people with…Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire
Objective: To prospectively measure the lessebo effect using an expectancy questionnaire (EQ). Background: The presence of a placebo arm in a randomized controlled trial has…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 388
- Next Page »